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Project Description: 
 
 The overall goal of this project was to develop simple and inexpensive tests to 
screen for the presence of early stage cancer in the residents of Nevada with a particular 
emphasis on the membership of the Hotel Employee Restaurant Employee International 
Union (HEREIU) in Las Vegas.  Our specific goals were: 
1) to develop a clinical database of individuals with cancer and to create a 
biological specimen Collection and Storage Systems (the NVCI bio-bank); 
2) to initiate screening of individuals for proteomic markers indicating 
susceptibility to or the presence of specific cancers, e.g. breast, ovarian, 
prostate and bladder.  In addition, we proposed the implementation of novel 
digital imaging technologies to detect melanoma; 
3) to genotype blood samples from individuals who consent to participate in IRB 
approved research studies using a high throughput single nucleotide 
polymorphisms (SNP) method based on optical thin-film biosensor chip 
technology; and 
4) to conduct biostatistical analysis of clinical, demographic, genetic, proteomic 
and digital imaging data to stratify the population cohort into relative risk 
groups for cancers that are prevalent in Nevada. 
 
 
Summary Project Report: 
 
Specific Aim 1: Clinical Database development, Sample Collection and Storage 
 
 Considerable progress was made in this objective during the funding period.  The 
HEREIU has a self-insured health plan that covers ~125,000 union employees and their 
family members.  They provided the Nevada Cancer Institute (NVCI), via a 
Memorandum of Agreement, access to the health records of all insured individuals and 
authority to develop programs that focus on early stage detection of cancers, outreach and 
education and patient navigation.  We utilized DOE funds to provide partial support for 
the development of a relational database that contains information on all individuals who 
were diagnosed with cancer between 1998 and 2002, how they were treated and what 
were the clinical outcomes.  This database provided baseline information by which the 
effectiveness of NVCI-HEREIU cancer navigation/education and intervention programs 
will be measured in the future.  In addition, comparison with data in the Nevada State 
cancer Registry, housed at NVCI, has identified discrepancies in the frequency of certain 
cancers between union members and the general population of Nevada.  Specifically, this 
study demonstrated that the frequency of breast cancer in the HEREIU cohort was 30% 
higher than in the state at large and that the rates of screening test, such as mammography 
and PAP smears, were considerable less than the national average.  These observations 
provided a strong incentive to establish a mobile mammography, phlebotomy and cancer 
screening unit, termed the Hope Coach, which will become operational in early 2007. 
 
 Utilizing funds provided by the DOE, we have established the resources and 
infrastructure needed to create a blood, urine and tissue banking facility at NVCI that will 
be collecting biological samples from patients who have consented to participate in IRB 
approved clinical trials at NVCI.  Since our clinical and research building opened to the 
public in September of 2005, samples from over 400 patients have been banked for 
research on cancer genetics and proteomic biomarker discovery.  To facilitate this 
ongoing enterprise, we have purchased multiple -80ºC freezers with independent alarm 
monitors for sample storage, barcode printers and scanners, a Freezer Works™ software 
system for maintenance of sample inventory and interfacing with the NVCI Electronic 
Medical Record database operational under the IMPAC control system.  Personnel have 
been trained in safety issues; sample collection protocols, ascertainment of informed 
consent and standard operating procedures for processing and storing patient samples 
have been implemented. 
 
 We also purchased/leased state-of-the-art equipment which was available to all 
NVCI faculty and their collaborators as core facilities.  These items included a Bio-Rad 
Luminex instrument for multiplex ELISA immunoassays using flow-sorted micro 
spheres, a Zymark robotic liquid handling system for high throughput processing of 
biological samples, a Genetix microarray printer for the preparation of investigator-
designed oligonucleotide and protein arrays, a processor for the preparation of tissue 
microarrays for immunohistochemical analysis of potential biomarkers and three dual 
384-head PCR machines for high throughput genotyping. 
 
Specific Aim 2: Clinical Screening 
 
 It was our original intention to utilize the resources outlined above to provide 
early stage cancer detection screening services to study volunteers from the HEREIU.  
Unfortunately, a definitive agreement between NVCI and the HEREIU as to where and 
when screening activities would be conducted was not concluded during the DOE 
funding period.  However as noted above, NVCI, in partnership with HEREIU and 
corporate backers, will be implementing the mobile Hope Coach program in early 2007.  
This will provide a mechanism to provide mammography, chest x-rays and blood and/or 
urine based cancer diagnostic tests on an ongoing basis.  It is anticipated that screening 
for breast, ovarian, prostate, lung and bladder cancer will be initiated in the near future.  
For technical reasons, our plan to screen for early stage melanoma using digital imaging 
technologies has been abandoned. 
 
Specific Aim 3: Genetic Analysis 
 
 Our original objective was to establish a high throughput SNP technology that 
could be used to genotype cancer-relevant genes from selected NVCI patient samples 
collected for the Bio-Bank.  We established a SNP typing capability that was based on 
robotic array printing on optical thin-film clips.  However, because of the significant 
improvements in SNP technology made by the commercial sector during the past two 
years, it is now most economical to conduct large scale SNP studies through contracts 
with a commercial provider.  Two SNP screening studies to identify biomarkers for 
cardiovascular disease and population based haplotype analysis for cancer susceptibility 
have been subcontracted to Illumina and over 7.5 million genotypings have been 
determined to date. 
 
Specific Aim 4: Biostatistical Analysis 
 
 Our utilization of biostatistical analysis has so far been limited to an ongoing 
study of serum-protein biomarkers for the early detection of ovarian cancer, a project that 
was initiated with DOE funding.  Both univariate and multivariate statistical analytical 
tools have been established for this and other projects.  The latter include support vector 
machines, three nearest neighbors, classification trees, e.g. Random Forest and Logistic 
Regression methods. 
 
 In conclusion, the direct and indirect funds provided by the DOE FY2004 
earmark (DE-FG02-04ER63863) have provided the resources and infrastructure to create 
state-of-the-art facilities to bank biological specimens and to conduct genomic and 
proteomic research related to the diagnosis, progression and therapy of cancer. 
 
 
 
 
 
 
 
  
